-
Akira
Mitsuhashi,
Yasunori
Sato,
T.
Kiyokawa,
M.
Koshizaka,
Hideki
Hanaoka,
Makio
Shozu
(2016)
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 2
-
(
YangBY
GulinaziY
DuY
, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020;127:848-857.31961463)
YangBY
GulinaziY
DuY
, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020;127:848-857.31961463
YangBY
GulinaziY
DuY
, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020;127:848-857.31961463,
YangBY
GulinaziY
DuY
, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020;127:848-857.31961463
-
(
YuM
WangY
YuanZ
, et al. Fertility-sparing treatment in young patients with grade 2 presumed stage IA endometrioid endometrial adenocarcinoma. Front Oncol. 2020;10:1437.32983972)
YuM
WangY
YuanZ
, et al. Fertility-sparing treatment in young patients with grade 2 presumed stage IA endometrioid endometrial adenocarcinoma. Front Oncol. 2020;10:1437.32983972
YuM
WangY
YuanZ
, et al. Fertility-sparing treatment in young patients with grade 2 presumed stage IA endometrioid endometrial adenocarcinoma. Front Oncol. 2020;10:1437.32983972,
YuM
WangY
YuanZ
, et al. Fertility-sparing treatment in young patients with grade 2 presumed stage IA endometrioid endometrial adenocarcinoma. Front Oncol. 2020;10:1437.32983972
-
C.
Meireles,
Sidney
Pereira,
L.
Valadares,
D.
Rêgo,
L.
Simeoni,
E.
Guerra,
A.
Lofrano-Porto
(2017)
Effects of metformin on endometrial cancer: Systematic review and meta-analysis.
Gynecologic oncology, 147 1
-
R.
Zhou,
Yuan
Yang,
Q.
Lu,
Jianliu
Wang,
Y.
Miao,
Shi-jun
Wang,
Zhiqi
Wang,
Chao
Zhao,
Lihui
Wei
(2015)
Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Gynecologic oncology, 139 3
-
(
MallikR
ChowdhuryTA.
Metformin in cancer. Diabetes Res Clin Pract. 2018;143:409-419.29807101)
MallikR
ChowdhuryTA.
Metformin in cancer. Diabetes Res Clin Pract. 2018;143:409-419.29807101
MallikR
ChowdhuryTA.
Metformin in cancer. Diabetes Res Clin Pract. 2018;143:409-419.29807101,
MallikR
ChowdhuryTA.
Metformin in cancer. Diabetes Res Clin Pract. 2018;143:409-419.29807101
-
Bing-Yi
Yang,
Yierfulati
Gulinazi,
Yan
Du,
Cheng-Cheng
Ning,
Ya-Li
Cheng,
Weiwei
Shan,
Xuezhen
Luo,
Hongwei
Zhang,
Q.
Zhu,
Fenghua
Ma,
Jia
Liu,
Li
Sun,
Min
Yu,
J.
Guan,
Xiao-Jun
Chen
(2020)
Metformin plus megestrol acetate compared with megestrol acetate alone as fertility‐sparing treatment in patients with atypical endometrial hyperplasia and well‐differentiated endometrial cancer: a randomised controlled trial
BJOG: An International Journal of Obstetrics & Gynaecology, 127
-
(
ParkJY
KimDY
KimTJ
, et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol. 2013;122:7-14.23743459)
ParkJY
KimDY
KimTJ
, et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol. 2013;122:7-14.23743459
ParkJY
KimDY
KimTJ
, et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol. 2013;122:7-14.23743459,
ParkJY
KimDY
KimTJ
, et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol. 2013;122:7-14.23743459
-
J.
Lortet-Tieulent,
J.
Ferlay,
F.
Bray,
A.
Jemal
(2018)
International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013.
Journal of the National Cancer Institute, 110 4
-
(
YangB
XuY
ZhuQ
, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153:55-62.30674421)
YangB
XuY
ZhuQ
, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153:55-62.30674421
YangB
XuY
ZhuQ
, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153:55-62.30674421,
YangB
XuY
ZhuQ
, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153:55-62.30674421
-
(
ShimSH
ChaeSH
SoKA
, et al. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer. Gynecol Oncol. 2021;161:810-816.33875233)
ShimSH
ChaeSH
SoKA
, et al. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer. Gynecol Oncol. 2021;161:810-816.33875233
ShimSH
ChaeSH
SoKA
, et al. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer. Gynecol Oncol. 2021;161:810-816.33875233,
ShimSH
ChaeSH
SoKA
, et al. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer. Gynecol Oncol. 2021;161:810-816.33875233
-
P.
Casadio,
Mariangela
Rosa,
Andrea
Alletto,
G.
Magnarelli,
A.
Arena,
Enrico
Fontana,
M.
Fabbri,
K.
Giovannico,
A.
Virgilio,
D.
Raimondo,
F.
Guasina,
R.
Paradisi,
R.
Seracchioli
(2020)
Fertility Sparing Treatment of Endometrial Cancer with and without Initial Infiltration of Myometrium: A Single Center Experience
Cancers, 12
-
A.
Mitsuhashi,
Y.
Habu,
Tatsuya
Kobayashi,
Yoshimasa
Kawarai,
H.
Ishikawa,
H.
Usui,
M.
Shozu
(2019)
Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
Journal of Gynecologic Oncology, 30
-
Yanan
Chang,
Ying
Zhang,
Yong-jun
Wang,
Li-ping
Wang,
H.
Duan
(2011)
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis.
Fertility and sterility, 96 4
-
Bingyi
Yang,
Yuhui
Xu,
Q.
Zhu,
Liying
Xie,
Weiwei
Shan,
C.
Ning,
Bingying
Xie,
Yue
Shi,
Xuezhen
Luo,
Hongwei
Zhang,
Xiaojun
Chen
(2019)
Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Gynecologic oncology, 153 1
-
A.
Raffone,
A.
Travaglino,
M.
Flacco,
Mara
Iasevoli,
A.
Mollo,
M.
Guida,
L.
Insabato,
A.
Sardo,
J.
Carugno,
F.
Zullo
(2020)
Clinical Predictive Factors of Response to Treatment in Patients Undergoing Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
Journal of adolescent and young adult oncology
-
(
ShanBE
RenYL
SunJM
, et al. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet. 2013;288:1115-1123.23644919)
ShanBE
RenYL
SunJM
, et al. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet. 2013;288:1115-1123.23644919
ShanBE
RenYL
SunJM
, et al. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet. 2013;288:1115-1123.23644919,
ShanBE
RenYL
SunJM
, et al. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet. 2013;288:1115-1123.23644919
-
(
CasadioP
GuasinaF
ParadisiR
LeggieriC
CapraraG
SeracchioliR.
Fertility-sparing treatment of endometrial cancer with initial infiltration of myometrium by resectoscopic surgery: a pilot study. Oncologist. 2018;23:478-480.29317550)
CasadioP
GuasinaF
ParadisiR
LeggieriC
CapraraG
SeracchioliR.
Fertility-sparing treatment of endometrial cancer with initial infiltration of myometrium by resectoscopic surgery: a pilot study. Oncologist. 2018;23:478-480.29317550
CasadioP
GuasinaF
ParadisiR
LeggieriC
CapraraG
SeracchioliR.
Fertility-sparing treatment of endometrial cancer with initial infiltration of myometrium by resectoscopic surgery: a pilot study. Oncologist. 2018;23:478-480.29317550,
CasadioP
GuasinaF
ParadisiR
LeggieriC
CapraraG
SeracchioliR.
Fertility-sparing treatment of endometrial cancer with initial infiltration of myometrium by resectoscopic surgery: a pilot study. Oncologist. 2018;23:478-480.29317550
-
F.
Falcone,
G.
Laurelli,
S.
Losito,
M.
Napoli,
V.
Granata,
S.
Greggi
(2016)
Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer
Journal of Gynecologic Oncology, 28
-
(
ChangYN
ZhangY
WangYJ
WangLP
DuanH.
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertil Steril. 2011;96:957-961.21872230)
ChangYN
ZhangY
WangYJ
WangLP
DuanH.
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertil Steril. 2011;96:957-961.21872230
ChangYN
ZhangY
WangYJ
WangLP
DuanH.
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertil Steril. 2011;96:957-961.21872230,
ChangYN
ZhangY
WangYJ
WangLP
DuanH.
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertil Steril. 2011;96:957-961.21872230
-
P.
Casadio,
F.
Guasina,
R.
Paradisi,
C.
Leggieri,
G.
Caprara,
R.
Seracchioli
(2018)
Fertility-Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study.
The oncologist, 23 4
-
(
FariaJ
NegalhaG
AzevedoA
MartelF.
Metformin and breast cancer: molecular targets. J Mammary Gland Biol Neoplasia. 2019;24:111-123.30903363)
FariaJ
NegalhaG
AzevedoA
MartelF.
Metformin and breast cancer: molecular targets. J Mammary Gland Biol Neoplasia. 2019;24:111-123.30903363
FariaJ
NegalhaG
AzevedoA
MartelF.
Metformin and breast cancer: molecular targets. J Mammary Gland Biol Neoplasia. 2019;24:111-123.30903363,
FariaJ
NegalhaG
AzevedoA
MartelF.
Metformin and breast cancer: molecular targets. J Mammary Gland Biol Neoplasia. 2019;24:111-123.30903363
-
Weiwei
Shan,
P.
Wu,
Bingyi
Yang,
Hongwei
Zhang,
Li
Sun,
Qiaoying
Lv,
Xuezhen
Luo,
Yali
Cheng,
Q.
Zhu,
Xiaojun
Chen
(2021)
Conservative management of grade 2 stage IA endometrial carcinoma and literature review
Journal of Obstetrics and Gynaecology Research, 47
-
(
YangYF
LiaoYY
LiuXL
SuSG
LiLZ
PengNF.
Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol. 2015;139:419-423.26494424)
YangYF
LiaoYY
LiuXL
SuSG
LiLZ
PengNF.
Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol. 2015;139:419-423.26494424
YangYF
LiaoYY
LiuXL
SuSG
LiLZ
PengNF.
Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol. 2015;139:419-423.26494424,
YangYF
LiaoYY
LiuXL
SuSG
LiLZ
PengNF.
Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol. 2015;139:419-423.26494424
-
A.
Raffone,
U.
Catena,
A.
Travaglino,
V.
Masciullo,
S.
Spadola,
L.
Corte,
A.
Piermattei,
L.
Insabato,
G.
Zannoni,
G.
Scambia,
F.
Zullo,
G.
Bifulco,
F.
Fanfani,
A.
Sardo
(2021)
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Gynecologic oncology
-
(
Lortet-TieulentJ
FerlayJ
BrayF
JemalA.
International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-361.29045681)
Lortet-TieulentJ
FerlayJ
BrayF
JemalA.
International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-361.29045681
Lortet-TieulentJ
FerlayJ
BrayF
JemalA.
International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-361.29045681,
Lortet-TieulentJ
FerlayJ
BrayF
JemalA.
International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-361.29045681
-
(
FebbraroT
LengyelE
RomeroIL.
Old drug, new trick: repurposing metformin for gynecologic cancers?
Gynecol Oncol
2014;135:614-621.25455733)
FebbraroT
LengyelE
RomeroIL.
Old drug, new trick: repurposing metformin for gynecologic cancers?
Gynecol Oncol
2014;135:614-621.25455733
FebbraroT
LengyelE
RomeroIL.
Old drug, new trick: repurposing metformin for gynecologic cancers?
Gynecol Oncol
2014;135:614-621.25455733,
FebbraroT
LengyelE
RomeroIL.
Old drug, new trick: repurposing metformin for gynecologic cancers?
Gynecol Oncol
2014;135:614-621.25455733
-
S.
Shim,
S.
Chae,
K.
So,
S.
Lee,
J.
Lee,
Tae
Kim,
E.
Han,
Soon-Beom
Kang
(2021)
Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
Gynecologic oncology
-
M.
Yu,
Yao
Wang,
Zhen
Yuan,
X.
Zong,
Xiao
Huo,
D.
Cao,
Jia-xin
Yang,
K.
Shen
(2020)
Fertility-Sparing Treatment in Young Patients With Grade 2 Presumed Stage IA Endometrioid Endometrial Adenocarcinoma
Frontiers in Oncology, 10
-
Yu-Feng
Yang,
Ying-Yang
Liao,
Xian
Liu,
Shu-guang
Su,
Lin-Zhu
Li,
N.
Peng
(2015)
Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment.
Gynecologic oncology, 139 3
-
S.
Acosta-Torres,
T.
Murdock,
R.
Matsuno,
A.
Beavis,
R.
Stone,
S.
Wethington,
K.
Levinson,
F.
Grumbine,
J.
Ferriss,
E.
Tanner,
A.
Fader
(2020)
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Gynecologic oncology
-
A.
Travaglino,
A.
Raffone,
G.
Saccone,
L.
Insabato,
A.
Mollo,
G.
Placido,
F.
Zullo
(2019)
Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review
Acta Obstetricia et Gynecologica Scandinavica, 98
-
(
ConcinN
Matias-GuiuX
VergoteI
, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12-39.33397713)
ConcinN
Matias-GuiuX
VergoteI
, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12-39.33397713
ConcinN
Matias-GuiuX
VergoteI
, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12-39.33397713,
ConcinN
Matias-GuiuX
VergoteI
, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12-39.33397713
-
Kamila
Trepka,
P.
Bodzek,
A.
Olejek
(2019)
Fertility-sparing treatment of endometrial cancer
Current Gynecologic Oncology
-
J.
Faria,
G.
Negalha,
A.
Azevedo,
Fátima
Martel
(2019)
Metformin and Breast Cancer: Molecular Targets
Journal of Mammary Gland Biology and Neoplasia
-
T.
Febbraro,
E.
Lengyel,
Iris
Romero
(2014)
Old drug, new trick: repurposing metformin for gynecologic cancers?
Gynecologic oncology, 135 3
-
(
Acosta-TorresS
MurdockT
MatsunoR
, et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: little impact on response and low live-birth rates. Gynecol Oncol. 2020;157:348-356.32085863)
Acosta-TorresS
MurdockT
MatsunoR
, et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: little impact on response and low live-birth rates. Gynecol Oncol. 2020;157:348-356.32085863
Acosta-TorresS
MurdockT
MatsunoR
, et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: little impact on response and low live-birth rates. Gynecol Oncol. 2020;157:348-356.32085863,
Acosta-TorresS
MurdockT
MatsunoR
, et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: little impact on response and low live-birth rates. Gynecol Oncol. 2020;157:348-356.32085863
-
F.
Falcone,
U.
Maggiore,
V.
Donato,
A.
Perrone,
L.
Frigerio,
G.
Bifulco,
S.
Polterauer,
P.
Casadio,
G.
Cormio,
V.
Masciullo,
M.
Malzoni,
S.
Greggi
(2020)
Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study
Journal of Gynecologic Oncology, 31
-
Danxia
Chu,
Jie
Wu,
Kaili
Wang,
Mengling
Zhao,
Chunfang
Wang,
Liuxia
Li,
R.
Guo
(2018)
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
BMC Cancer, 18
-
Zhi
Yang,
Xun
Ding,
Jiang
Liu,
P.
Duan,
L.
Si,
Binghua
Wan,
P.
Tu
(2017)
Associations between anthropometric parameters and lipid profiles in Chinese individuals with age ≥40 years and BMI <28kg/m2
PLoS ONE, 12
-
(
YangZ
DingX
LiuJ
, et al. Associations between anthropometric parameters and lipid profiles in Chinese individuals with age >/=40 years and BMI <28kg/m2. PLoS ONE. 2017;12:e0178343.)
YangZ
DingX
LiuJ
, et al. Associations between anthropometric parameters and lipid profiles in Chinese individuals with age >/=40 years and BMI <28kg/m2. PLoS ONE. 2017;12:e0178343.
YangZ
DingX
LiuJ
, et al. Associations between anthropometric parameters and lipid profiles in Chinese individuals with age >/=40 years and BMI <28kg/m2. PLoS ONE. 2017;12:e0178343.,
YangZ
DingX
LiuJ
, et al. Associations between anthropometric parameters and lipid profiles in Chinese individuals with age >/=40 years and BMI <28kg/m2. PLoS ONE. 2017;12:e0178343.
-
(
ZhouR
YangY
LuQ
, et al. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol Oncol. 2015;139:424-428.26428941)
ZhouR
YangY
LuQ
, et al. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol Oncol. 2015;139:424-428.26428941
ZhouR
YangY
LuQ
, et al. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol Oncol. 2015;139:424-428.26428941,
ZhouR
YangY
LuQ
, et al. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol Oncol. 2015;139:424-428.26428941
-
Ritwika
Mallik,
T.
Chowdhury
(2018)
Metformin in cancer.
Diabetes research and clinical practice, 143
-
A.
Raffone,
A.
Travaglino,
G.
Saccone,
A.
Mollo,
G.
Placido,
L.
Insabato,
F.
Zullo
(2019)
Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta‐analysis
Acta Obstetricia et Gynecologica Scandinavica, 98
-
B.
Shan,
Y.
Ren,
Jian-min
Sun,
X.
Tu,
Z.
Jiang,
X.
Ju,
R.
Zang,
Huaying
Wang
(2013)
A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women
Archives of Gynecology and Obstetrics, 288
-
J.
Park,
Daeyeon
Kim,
Tae‐Jin
Kim,
Jae
Kim,
Jong-Hyeok
Kim,
Yong-Man
Kim,
Young-Tak
Kim,
D.
Bae,
J.
Nam
(2013)
Hormonal Therapy for Women With Stage IA Endometrial Cancer of All Grades
Obstetrics & Gynecology, 122
-
(
ShanW
WuP
YangB
, et al. Conservative management of grade 2 stage IA endometrial carcinoma and literature review. J Obstet Gynaecol Res. 2021;47:984-991.33403812)
ShanW
WuP
YangB
, et al. Conservative management of grade 2 stage IA endometrial carcinoma and literature review. J Obstet Gynaecol Res. 2021;47:984-991.33403812
ShanW
WuP
YangB
, et al. Conservative management of grade 2 stage IA endometrial carcinoma and literature review. J Obstet Gynaecol Res. 2021;47:984-991.33403812,
ShanW
WuP
YangB
, et al. Conservative management of grade 2 stage IA endometrial carcinoma and literature review. J Obstet Gynaecol Res. 2021;47:984-991.33403812
-
(
MeirelesCG
PereiraSA
ValadaresLP
, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. 2017;147:167-180.28760367)
MeirelesCG
PereiraSA
ValadaresLP
, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. 2017;147:167-180.28760367
MeirelesCG
PereiraSA
ValadaresLP
, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. 2017;147:167-180.28760367,
MeirelesCG
PereiraSA
ValadaresLP
, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. 2017;147:167-180.28760367
-
(
MitsuhashiA
SatoY
KiyokawaT
KoshizakaM
HanaokaH
ShozuM.
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27:262-266.26578736)
MitsuhashiA
SatoY
KiyokawaT
KoshizakaM
HanaokaH
ShozuM.
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27:262-266.26578736
MitsuhashiA
SatoY
KiyokawaT
KoshizakaM
HanaokaH
ShozuM.
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27:262-266.26578736,
MitsuhashiA
SatoY
KiyokawaT
KoshizakaM
HanaokaH
ShozuM.
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27:262-266.26578736
-
(
TravaglinoA
RaffoneA
SacconeG
, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019;98:1086-1099.30793281)
TravaglinoA
RaffoneA
SacconeG
, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019;98:1086-1099.30793281
TravaglinoA
RaffoneA
SacconeG
, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019;98:1086-1099.30793281,
TravaglinoA
RaffoneA
SacconeG
, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019;98:1086-1099.30793281
-
N.
Concin,
X.
Matías-Guiu,
I.
Vergote,
D.
Cibula,
M.
Mirza,
S.
Marnitz,
J.
Ledermann,
T.
Bosse,
Cyrus
Chargari,
A.
Fagotti,
C.
Fotopoulou,
A.
Martín,
S.
Lax,
D.
Lorusso,
C.
Marth,
P.
Morice,
R.
Nout,
D.
O'Donnell,
D.
Querleu,
M.
Raspollini,
J.
Sehouli,
A.
Sturdza,
Alexandra
Taylor,
A.
Westermann,
P.
Wimberger,
N.
Colombo,
F.
Planchamp,
C.
Creutzberg
(2020)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, 31
-
(
FalconeF
LaurelliG
LositoS
Di NapoliM
GranataV
GreggiS.
Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28:e2.)
FalconeF
LaurelliG
LositoS
Di NapoliM
GranataV
GreggiS.
Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28:e2.
FalconeF
LaurelliG
LositoS
Di NapoliM
GranataV
GreggiS.
Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28:e2.,
FalconeF
LaurelliG
LositoS
Di NapoliM
GranataV
GreggiS.
Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28:e2.
-
(
ChuD
WuJ
WangK
, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC Cancer. 2018;18:438.29669520)
ChuD
WuJ
WangK
, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC Cancer. 2018;18:438.29669520
ChuD
WuJ
WangK
, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC Cancer. 2018;18:438.29669520,
ChuD
WuJ
WangK
, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC Cancer. 2018;18:438.29669520
-
A.
Raffone,
A.
Travaglino,
Francesco
Zullo,
Annarita
Gencarelli,
M.
Micheli,
Sergio
Miranda,
P.
Franciscis,
L.
Insabato,
A.
Sardo,
F.
Zullo,
G.
Bifulco
(2020)
Predictive accuracy of progesterone receptor B in young women with atypical endometrial hyperplasia and early endometrial cancer treated with hysteroscopic resection plus LNG-IUD insertion.
Journal of minimally invasive gynecology
-
(
RaffoneA
CatenaU
TravaglinoA
, et al. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study. Gynecol Oncol. 2021;161:795-801.33812697)
RaffoneA
CatenaU
TravaglinoA
, et al. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study. Gynecol Oncol. 2021;161:795-801.33812697
RaffoneA
CatenaU
TravaglinoA
, et al. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study. Gynecol Oncol. 2021;161:795-801.33812697,
RaffoneA
CatenaU
TravaglinoA
, et al. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study. Gynecol Oncol. 2021;161:795-801.33812697